Read, Watch or Listen

Moderna lowered its 2025 revenue outlook due to a delayed UK vaccine shipment, but exceeded Q2 expectations. Revenue is now projected between $1.5 billion and $2.2 billion. The company also announced a 10% workforce reduction amidst falling Covid vaccine sales. Despite a 41% year-over-year revenue drop to $142 million in Q2 (beating estimates), Moderna's loss per share ($2.13) was less than anticipated. Cost-cutting measures contributed to exceeding Q2 expectations.

Prepared by Christopher Adams and reviewed by editorial team.